Abstract
Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.
MeSH terms
-
Adult
-
Alemtuzumab
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use*
-
Antilymphocyte Serum / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Cyclosporine / administration & dosage
-
Dexamethasone / administration & dosage
-
Drug Resistance, Neoplasm*
-
Humans
-
Leukemia, T-Cell / complications
-
Leukemia, T-Cell / drug therapy*
-
Male
-
Mitoxantrone / administration & dosage
-
Prednisolone / administration & dosage
-
Red-Cell Aplasia, Pure / complications
-
Red-Cell Aplasia, Pure / drug therapy*
-
Remission Induction
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antilymphocyte Serum
-
Antineoplastic Agents
-
Alemtuzumab
-
Dexamethasone
-
Cyclosporine
-
Cyclophosphamide
-
Prednisolone
-
Mitoxantrone
-
Vidarabine
-
fludarabine